
|Articles|August 19, 2019
ASRS 2019 Street Team: Raj K. Maturi, MD
Author(s)Julianne Mobilian
ICYMI: Abicipar Phase II MAPLE Trial supports improved safety for patients with nAMD following a Modified Manufacturing Process
Advertisement
Raj K. Maturi, MD, discusses phase II data from the abicipar Phase II MAPLE Trial for patients with AMD at the 2019 annual ASRS conference.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
From AI to injury patterns: Insights from emerging ophthalmic research
2
FLORetina 2025: Reframing retinal disease through the lens of choroidal health
3
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
4
FLORetina 2025: Navigating antithrombotic therapy in wet AMD
5













































